(Press-News.org) Seattle, United States & Seoul, Republic of Korea—PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.® Multi-dose is manufactured by EuBiologics Co., LTD, Republic of Korea. The results, published in The Lancet Global Health, demonstrate that EuTYPH-C Inj.® Multi-dose is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa.
The study was conducted at sites in Kenya and Senegal in healthy adults, children, and infants, and evaluated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The study also assessed co-administration of EuTYPH-C Inj.® Multi-dose with measles-rubella and yellow fever vaccines at 9-12 months of age and antibody levels over 6 months.
“Safety is of paramount importance when evaluating a new vaccine. EuTYPH-C Inj.® Multi-dose was shown to be well tolerated across all age groups, with a similar safety profile to the comparator vaccine,” says Patricia Njuguna, Senior Medical Officer, and project lead of the study from PATH. “No safety concerns were identified, with no serious adverse events related to vaccination noted.”
Immunogenicity, which measures the body’s immune response, was evaluated in participants 9 to 12 months of age. Immune responses from both single-dose and multi-dose presentations of EuTYPH-C Inj.® Multi-dose were non-inferior to Typbar TCV at 28 days post-vaccination. Seroconversion rates were high at 28 days post-vaccination and remained high at 6 months post-vaccination. Additionally, coadministration of EuTYPH-C Inj.® Multi-dose with other childhood vaccines did not interfere with immune responses to the different pathogens.
“These results are a positive step toward our goal of providing a safe and effective vaccine to prevent typhoid in endemic areas. They are the pivotal data that supported licensure from the Korean Ministry of Food and Drug Safety and will support WHO prequalification, which is our next step for this vaccine,” says Youngjin Choi, Managing Director, Clinical Development Division, EuBiologics Co., LTD. “We welcome the results from this trial and are looking forward to supplying EuTYPH-C Inj.® Multi-dose to countries with a high burden of typhoid.”
WHO prequalification is a designation that ensures a vaccine meets strict international quality, safety, and efficacy standards and that allows it to be procured by United Nations agencies and Gavi, the Vaccine Alliance. There are currently four prequalified TCV products, two of which are available for Gavi-eligible countries. Additional products from diverse manufacturers help to drive down vaccine prices, maintain a strong healthy supply, and increase access.
“Demand for TCVs in Gavi-eligible typhoid endemic countries has been high. To date, seven Gavi-eligible countries have introduced TCV, with several more in various stages of the planning and introduction process,” says Dr. Emmanuel Mugisha, Global Director for Vaccine Implementation and Director of TyVAC at PATH, a consortium that aims to accelerate the introduction of TCVs in typhoid-endemic countries. “The potential for an additional product will help ensure a stable vaccine supply for countries interested in introducing TCV as part of their typhoid prevention and control plans.”
This study enrolled 3,219 healthy participants aged 6 months to 45 years old at two study sites in Kericho, Kenya, and Sandiara, Senegal. Study partners included PATH, EuBiologics Co., LTD, Kenya Medical Research Institute (KEMRI)-Walter Reed Army Institute of Research (WRAIR) Kericho, and Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF). The study was funded by EuBiologics Co., LTD and the RIGHT Foundation grant number RF-2021-V01.
Typhoid is a serious and potentially life-threatening illness that primarily impacts children younger than 15 years old in Asia and sub-Saharan Africa. The Global Burden of Disease study estimates that in 2021, there were more than 7 million cases and more than 93,000 deaths due to typhoid. While typhoid is treatable with antibiotics, drug resistant typhoid is increasing, raising the urgency for preventative measures including TCVs and improvements to water, sanitation, and hygiene. More than 90 million children have been vaccinated with TCVs through introduction campaigns so far.
Media contacts:
PATH: media@path.org
EuBiologics Co., LTD: info@eubiologics.com
About PATH
PATH is a global nonprofit dedicated to achieving health equity. With more than 40 years of experience forging multisector partnerships, and with expertise in science, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales up innovative solutions to the world’s most pressing health challenges. For more information, visit https://www.path.org.
About EuBiologics Co., LTD
EuBiologics Co., LTD, headquartered in Seoul, Republic of Korea, is a specialized developer of both preventive and therapeutic vaccines. The company is focused on building a diverse pipeline that includes bacterial and viral vaccines for infectious disease prevention, as well as personalized therapeutic vaccines. EuBiologics Co., LTD exclusively supplies its WHO-prequalified oral cholera vaccine to UNICEF, playing a key role in the global public health market. Leveraging its proprietary vaccine platforms, the company is also advancing premium vaccine development and provides customized CRMO services for biopharmaceuticals. For more information, please visit the website (http://eubiologics.com/eng/).
END
EuTYPH-C Inj.® Multi-dose demonstrates strong safety and immunogenicity: Results now available from a Phase 3 study
2025-11-13
ELSE PRESS RELEASES FROM THIS DATE:
Fossil fuel CO2 emissions hit record high in 2025
2025-11-13
Global carbon emissions from fossil fuels are projected to rise by 1.1% in 2025 – reaching a record high, according to new research by the Global Carbon Project.
The 2025 Global Carbon Budget projects 38.1 billion tonnes of fossil carbon dioxide (CO2) emissions this year.
Decarbonisation of energy systems is progressing in many countries – but this is not enough to offset the growth in global energy demand.
With projected emissions from land-use change (such as deforestation) down to 4.1 billion ...
Bold action needed to fix NHS clinical placement crisis
2025-11-13
A fundamental rethink of how the NHS trains its future workforce is urgently needed, according to a new paper from the Higher Education Policy Institute (www.hepi.ac.uk), Rethinking Placement: Increasing Clinical Placement Efficacy for a Sustainable NHS Future (HEPI Report 194).
The paper, written by senior leaders from the University of East London (UEL), argues that the National Health Service (NHS) cannot achieve its ambitious workforce goals without bold system-wide reform of how students gain real-world experience – the essential bridge between classroom learning and frontline care.
The HEPI Report, which has been published with the support of the Council for Deans ...
Six strategies to reinvigorate the doctor-patient bedside encounter
2025-11-12
Most commonly reported error in the physical exam is that the exam was never performed
Report in the New England Journal of Medicine is part of a six-issue series on medical education
‘If we don’t intentionally cultivate these bedside skills, they’re at risk of being lost’
CHICAGO --- Today’s doctor visits look and feel a lot different than they did even just a couple decades ago.
Rushed physicians and medical trainees are spending less time with patients, leading to diagnostic errors, ...
Mount Sinai study reveals why some myeloma patients stay cancer-free for years after CAR T therapy
2025-11-12
New York, NY (November 12, 2025) – A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.
Published in Blood Advances, the research is the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma. Cilta-cel (ciltacabtagene autoleucel) is a type of CAR T cell therapy used to treat relapsed or refractory multiple myeloma. It works ...
How climate change brings wildlife to the yard
2025-11-12
As climate change increases the frequency of droughts, UCLA and UC Davis researchers found one overlooked side effect: People report more conflicts with wildlife during drought, when resources are scarce.
For every inch that annual rainfall decreases, scientists found a 2% to 3% increase in reported clashes with a variety of carnivores during drought years, according to a paper published today, Nov. 12, in the journal Science Advances.
The researchers pored through seven years of data from the Wildlife Incident Reporting database, run by the California Department of Fish and Wildlife. The results are likely broadly applicable outside of California, said lead author Kendall Calhoun, ...
Plants balance adaptability in skin cells with stability in sex cells
2025-11-12
Mutations drive evolution, but they can also be risky. New research led by plant biologists at the University of California, Davis, published Nov. 10 in Proceedings of the National Academy of Sciences, reveals how plants control mutation rates in different stem cells to balance adaptability with safety and stability. The findings have implications for breeding some of the world’s most important fruit and vegetable crops, such as potatoes and bananas.
The researchers showed that DNA mutations accumulated up to 4.5 times more frequently in the stem cells that produce a plant’s ...
UH Wolff Center for Entrepreneurship ranked No. 1 for seventh consecutive year
2025-11-12
The Cyvia and Melvyn Wolff Center for Entrepreneurship in the University of Houston’s C.T. Bauer College of Business has once again been named the No. 1 undergraduate entrepreneurship program.
The Wolff Center is the first undergraduate program to secure seven consecutive No. 1 rankings on The Princeton Review’s list, besting its own record of six consecutive wins in the 2025 ranking last November.
Each year, The Princeton Review ranks undergraduate and graduate entrepreneurship programs based on a survey of nearly 300 schools across the U.S., Canada, Mexico and Europe. ...
New study reveals long-term impacts on Stevens-Johnson syndrome survivors
2025-11-12
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) survivors encounter rare, life-threatening drug reactions and years of physical, emotional and social consequences long after leaving the hospital, according to a study published today in JAMA Dermatology.
Investigators from Vanderbilt University Medical Center’s Center for Drug Safety and Immunology (CDSI), in collaboration with the VUMC Qualitative Research Core, conducted one of the largest qualitative studies in the United States exploring SJS/TEN recovery and long-term residual effects from the patients’ ...
New study reveals how your income may shape your risk of dementia
2025-11-12
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, NOVEMBER 12, 2025
Highlights:
Your income may be associated with your risk factors for dementia.
Researchers found that having a lower income was associated with a higher prevalence of dementia risk factors like hearing loss, high blood pressure, depression and physical inactivity.
For people living below the poverty level, one in five cases of dementia may be associated with vision loss and social isolation in older people.
After adjusting for income, several risk factors still showed higher prevalence among historically underrepresented groups in clinical research, including diabetes, physical inactivity, obesity and vision ...
Texas A&M researchers use AI to identify genetic ‘time capsule’ that distinguishes species
2025-11-12
In a groundbreaking study, scientists from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) have utilized cutting-edge artificial intelligence methods to identify a region of the X chromosome that has maintained the distinctiveness of mammal species for millions of years.
Their findings shed new light on how species maintain their genetic identity, even when hybridization acts to homogenize their gene pools.
“We know that species like big cats; wolves, dogs and coyotes; and even whales and dolphins have interbred ...